Despite 'lackluster' 2022, PwC remains 'bullish' on pharma M&A in 2023

While 2022 was shaping up to be a busy year for M&A, PwC recorded an overall “lackluster” amount of activity, with both deal size and volume down from last year. However, the accounting firm predicts a 2023 rebound.

In its latest deals outlook report, PwC predicted a more active 2023, with “M&A to more closely resemble prior years with a total deal value in the $225 billion to $275 billion range across all subsectors.”